gepotidacin (Blujepa)
Jump to navigation
Jump to search
Indications
- treatment of uncomplicated urinary tract infections*[1] (UTIs)
- treatment of uncomplicated urogenital gonorrhea#[2]
* non-inferior to nitrofurantoin for treatment of uncomplicated UTIs
* FDA-approved March 2025
# non-inferior to ceftriaxone plus azithromycin for urogenital N gonorrhoeae[2]
Dosage
Antimicrobial activity
- common uropathogens, including clinically important drug-resistant organisms
Adverse effects
- diarrhea (14%)
Mechanism of action
- inhibits bacterial DNA replication
- inhibition of two type II topoisomerase enzymes
More general terms
References
- ↑ 1.0 1.1 Wagenlehner F, Perry CR, Hooton TM et al Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double- dummy, phase 3, non-inferiority trials. Lancet. 2024 Feb 8:S0140-6736(23)02196-7. PMID: https://pubmed.ncbi.nlm.nih.gov/38342126
Wagenlehner F, Perry CR, Hooton TM et al et al. Plain language summary: Efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection. Future Microbiol 2025 Mar; 20:265-275 PMID: https://pubmed.ncbi.nlm.nih.gov/39988828 PMCID: PMC11951693 https://www.tandfonline.com/doi/abs/10.1080/17460913.2025.2460387 - ↑ 2.0 2.1 2.2 2.3 Ross JDC, Wilson J, Workowski KA et al Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet. 2025 Apr 11:S0140-6736(25)00628-2 PMID: https://pubmed.ncbi.nlm.nih.gov/40245902 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00628-2/abstract